Skip to content

A Randomized Controlled Pilot Study on Mindfulness-Based Cognitive Therapy for Unipolar Depression in Patients With Chronic Pain.

Marasha De Jong, Frenk Peeters, Tim Gard, Heidi Ashih, Jim Doorley, Rosemary Walker, Laurie Rhoades, Ronald J Kulich, Karsten D Kueppenbender, Jonathan E. Alpert, Elizabeth A Hoge, Willoughby B. Britton, Sara W. Lazar, Maurizio Fava, David Mischoulon

The Journal of Clinical Psychiatry 2018 DOI: 10.4088/jcp.15m10160 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Randomized controlled pilot study Peer reviewed
Sample size 40
Population Adults with chronic pain lasting at least 3 months and a DSM-IV depressive disorder (major depressive disorder, dysthymic disorder, or depressive disorder not otherwise specified) with a QIDS-C16 score of 6 or higher
Intervention Mindfulness-based cognitive therapy (MBCT)
Duration 8 sessions; data collection January 2012 to July 2013
Measures 16-item Quick Inventory of Depressive Symptomatology-Clinician Rated (QIDS-C16), 17-item Hamilton Depression Rating Scale (HDRS17)
Topics Depression Meditation
Registration NCT01473615
Key points In the intention-to-treat sample, MBCT did not significantly differ from waitlist on depression outcomes. In the per-protocol sample of 33 participants, MBCT produced a significant treatment-by-time interaction on QIDS-C16 depression scores, with a large decrease in the MBCT group but not the control group; Hamilton Depression Rating Scale scores did not differ significantly between groups. The authors conclude MBCT shows potential for treating depression in chronic pain, but larger controlled trials are needed.

Abstract

Chronic pain is a disabling illness, often comorbid with depression. We performed a randomized controlled pilot study on mindfulness-based cognitive therapy (MBCT) targeting depression in a chronic pain population. Participants with chronic pain lasting ≥ 3 months; DSM-IV major depressive disorder (MDD), dysthymic disorder, or depressive disorder not otherwise specified; and a 16-item Quick Inventory of Depressive Symptomatology-Clinician Rated (QIDS-C₁₆) score ≥ 6 were randomly assigned to MBCT (n = 26) or waitlist (n = 14). We adapted the original MBCT intervention for depression relapse prevention by modifying the psychoeducation and cognitive-behavioral therapy elements to an actively depressed chronic pain population. We analyzed an intent-to-treat (ITT) and a per-protocol sample; the per-protocol sample included participants in the MBCT group who completed at least 4 of 8 sessions. Changes in scores on the QIDS-C₁₆ and 17-item Hamilton Depression Rating Sale (HDRS₁₇) were the primary outcome measures. Pain, quality of life, and anxiety were secondary outcome measures. Data collection took place between January 2012 and July 2013. Nineteen participants (73%) completed the MBCT program. No significant adverse events were reported in either treatment group. ITT analysis (n = 40) revealed no significant differences. Repeated-measures analyses of variance for the per-protocol sample (n = 33) revealed a significant treatment × time interaction (F₁,₃₁ = 4.67, P = .039, η²p = 0.13) for QIDS-C₁₆ score, driven by a significant decrease in the MBCT group (t₁₈ = 5.15, P < .001, d = >1.6), but not in the control group (t₁₃ = 2.01, P = .066). The HDRS₁₇ scores did not differ significantly between groups. The study ended before the projected sample size was obtained, which might have prevented effect detection in some outcome measures. MBCT shows potential as a treatment for depression in individuals with chronic pain, but larger controlled trials are needed. ClinicalTrials.gov identifier: NCT01473615.

Comparable studies

Other randomized controlled trials on depression, most cited first.

Study Year Design Participants
A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major Depression Subjects with DSM-IV major depression (treatment resistant) 2006 Randomized, placebo-controlled, double-blind crossover study n = 18
Prevention of relapse/recurrence in major depression by mindfulness-based cognitive therapy. Recovered recurrently depressed patients 2000 Randomized controlled trial n = 145
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Cancer patients with life-threatening diagnoses and symptoms of depression and/or anxiety 2016 Randomized controlled trial n = 51
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Patients with cancer-related anxiety and depression 2016 Double-blind, placebo-controlled, crossover trial n = 29
Mindfulness-Based Cognitive Therapy for Depression: Replication and Exploration of Differential Relapse Prevention Effects. Recovered recurrently depressed patients 2004 Randomized controlled trial n = 73

Citations in the library

Explore topics